Zhendong Pharmacy established a refined wall-breaking decoction pieces technology company

According to the Qichacha APP, recently, Shanxi Zhendong Precision Broken Wall Herbal Slice Technology Co., Ltd. was established, with Guan Tao as the legal representative and a registered capital of 10 million yuan. The business scope includes: planting of Chinese herbal medicine; production of traditional Chinese medicine extracts; acquisition of Chinese herbal medicine; food sales; production of health food; production of pharmaceuticals; entrusted production of pharmaceuticals, etc. Qichacha's equity penetration shows that the company is wholly owned by Shanxi Zhendong Authentic Medicinal Materials Development Co., Ltd., a subsidiary of Zhendong Pharmacy

Zhendong Pharmacy released its performance for the first three quarters, with a net profit attributable to the parent company of 20.3641 million yuan, a decrease of 49.25%

Zhendong Pharmacy released its Q3 2025 report, with operating revenue for the first three quarters at 2.215 billion yuan, a year-on-year decrease of 2.42%. The net profit attributable to the parent company was 20.3641 million yuan, a year-on-year decline of 49.25%. The net profit after deducting non-recurring gains and losses was 507,500 yuan, a year-on-year increase of 101.67%. The basic earnings per share were 0.0203 yuan

Innovative drug concept stocks fell in the afternoon, with Staidson BioPharm down over 10%

Innovative drug concept stocks fell in the afternoon, with Staidson BioPharm down over 10%, Thalys nearing its limit down, Cosunter down over 9%, and ALK and Zhendong Pharmacy among the biggest decliners

Zhendong Pharmacy: Adjusting the upper limit of the repurchase price to RMB 11.40 per share

Zhendong Pharmacy announced that in order to ensure the smooth implementation of the share repurchase plan, the upper limit of the repurchase price will be adjusted from RMB 6.00 per share to RMB 11.40 per share. This price does not exceed 150% of the average trading price of the company's stock over the 30 trading days prior to the board's approval of the adjustment proposal. The adjusted upper limit of the repurchase price will take effect from August 25, 2025. The total repurchase amount will not be less than RMB 50 million and not exceed RMB 100 million

The A-share traditional Chinese medicine sector rapidly surged, with Xintian Pharma hitting the limit up, and YIBAI PHARMACEUTICAL, Zhendong Pharmacy, ZHONGSHENGYAOYE, Hansen Pharmaceutical, and ENWEI PHARMACEUTICAL following suit